Anbio Biotechnology – Information to SEC and Nasdaq
Anbio – Regulator Information Letter
Written by
Written by
Anbio Biotechnology – Information to SEC and Nasdaq
We believe that publishing our opinion is in public interest.
By viewing material on this website you agree to the following Terms of Service. Use of the research of HitHawk Research ("HitHawk"), a BlackStyx Capital LLC brand, is at your own risk. To the best of HitHawk’s ability and belief, all information contained herein is accurate, reliable, and provided “as is”. HitHawk disclaims making any express or implied warranties with respect to accuracy of third party statements or citations, the completeness of provided information, and the fitness of the information contained herein for any particular usage, its merchantability, and/or its application or purpose.
Nothing on this website shall be deemed an offer or solicitation to purchase or sell services. HitHawk uses this website solely to discuss its opinions and investment ideas. HitHawk has no intention of soliciting prospective clients for any products or services. In no event shall HitHawk be responsible or liable for the correctness of any such material or for any damage or lost opportunities resulting from use of this data. Prior to making any investment you should consult with professional financial, legal, and tax advisors to assist in due diligence as may be appropriate and determining the appropriateness of the risk associated with a particular investment.
You should assume that as of the publication date of any report, post or communication referencing any publicly traded security, HitHawk (possibly along with or through our members, partners, affiliates, employees, clients, investors, industry contacts and/or consultants) may have a position in the stock, bonds, derivatives or other securities covered herein, and therefore stands to realize significant gains in the event that the price of the securities move. Following publication of any report or letter, HitHawk intends to continue transacting in the securities covered therein and may be long, short, or neutral at any time thereafter regardless of HitHawk’s initial position or views. HitHawk’s investments are subject to its risk management guidance, which may result in the derisking of some or all of its positions at any time following publication of any report or letter depending on security-specific, market or other relevant conditions. If any provision in this Disclaimer is held to be invalid or unenforceable, then the remaining provisions shall continue in full force and effect.
Users of the website (“Users”) shall not use it at any time for any purpose that is unlawful or prohibited and, at all relevant times, shall comply with any applicable local, state, national or international laws or regulations.
HitHawk and the terms, logos and marks included on this website that identify HitHawk’s services and products are proprietary materials. Copyright in the pages and in the screens of the website, and in the information and material therein, is proprietary material owned by HitHawk Research unless otherwise indicated. Unless otherwise noted, all information provided on this website is provided by HitHawk and is subject to copyright and trademark laws. Logos and marks contained in links to third party websites belong to their respective owners.
Any links from our site are provided for viewer convenience. HitHawk is not associated or affiliated with any linked sites. Independent providers have prepared all information accessible through these links.